{"entity":{"type":"insider","cik":"0001914503","url":"/insider/0001914503","json_url":"/insider/0001914503.json","name":"Easom Eric","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":26,"n_filings":11,"first":"2022-10-24","last":"2025-06-03","span_basis":"filed_date"},"name_variants":[{"name":"Easom Eric","source":"filing","n_filings":11,"first_seen":"2022-10-24","last_seen":"2025-06-03"}],"transactions":[{"id":4946710,"accession":"0000950170-25-081041","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-081041","line_url":"/filing/0000950170-25-081041#line-1","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":1.0665,"price_display":"1.07","price_state":"stated","total_value":10665.0,"total_display":"10,665.00","total_whole":"10,665","shares_owned_after":256380.0,"shares_owned_after_display":"256,380","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-02","filed_date":"2025-06-03","scope":"insider"},{"id":2467390,"accession":"0000950170-24-128202","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-128202","line_url":"/filing/0000950170-24-128202#line-1","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":0.9994,"price_display":"1.00","price_state":"stated","total_value":49970.0,"total_display":"49,970.00","total_whole":"49,970","shares_owned_after":1065766.0,"shares_owned_after_display":"1,065,766","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-18","filed_date":"2024-11-18","scope":"insider"},{"id":2122363,"accession":"0001610717-24-000013","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-24-000013","line_url":"/filing/0001610717-24-000013#line-1","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2777.0,"shares_display":"2,777","price_per_share":20.0945,"price_display":"20.09","price_state":"stated","total_value":55802.4265,"total_display":"55,802.43","total_whole":"55,802","shares_owned_after":2130.0,"shares_owned_after_display":"2,130","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-04","scope":"insider"},{"id":8694497,"accession":"0000899243-23-013012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-013012","line_url":"/filing/0000899243-23-013012#line-1","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":5.377,"price_display":"5.38","price_state":"stated","total_value":53770.0,"total_display":"53,770.00","total_whole":"53,770","shares_owned_after":1015766.0,"shares_owned_after_display":"1,015,766","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-15","filed_date":"2023-05-15","scope":"insider"},{"id":6804802,"accession":"0000899243-22-035782","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-035782","line_url":"/filing/0000899243-22-035782#line-2","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23.0,"shares_display":"23","price_per_share":15.04,"price_display":"15.04","price_state":"stated","total_value":345.92,"total_display":"345.92","total_whole":"346","shares_owned_after":4907.0,"shares_owned_after_display":"4,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-14","filed_date":"2022-11-14","scope":"insider"},{"id":6804798,"accession":"0000899243-22-035782","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-035782","line_url":"/filing/0000899243-22-035782#line-1","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4413.0,"shares_display":"4,413","price_per_share":15.3248,"price_display":"15.32","price_state":"stated","total_value":67628.3424,"total_display":"67,628.34","total_whole":"67,628","shares_owned_after":4930.0,"shares_owned_after_display":"4,930","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-10","filed_date":"2022-11-14","scope":"insider"},{"id":6714879,"accession":"0000899243-22-035472","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-035472","line_url":"/filing/0000899243-22-035472#line-3","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10111.0,"shares_display":"10,111","price_per_share":15.6114,"price_display":"15.61","price_state":"stated","total_value":157846.8654,"total_display":"157,846.87","total_whole":"157,847","shares_owned_after":4907.0,"shares_owned_after_display":"4,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-09","filed_date":"2022-11-09","scope":"insider"},{"id":6714876,"accession":"0000899243-22-035472","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-035472","line_url":"/filing/0000899243-22-035472","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7055.0,"shares_display":"7,055","price_per_share":15.584233593196315,"price_display":"15.58","price_state":"stated","total_value":109946.768,"total_display":"109,946.77","total_whole":"109,947","shares_owned_after":16273.0,"shares_owned_after_display":"16,273","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-08","filed_date":"2022-11-09","scope":"insider","n_lines":2},{"id":6386618,"accession":"0000899243-22-035311","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-035311","line_url":"/filing/0000899243-22-035311","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12203.0,"shares_display":"12,203","price_per_share":16.040410874375155,"price_display":"16.04","price_state":"stated","total_value":195741.1339,"total_display":"195,741.13","total_whole":"195,741","shares_owned_after":6943.0,"shares_owned_after_display":"6,943","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-07","filed_date":"2022-11-07","scope":"insider","n_lines":2},{"id":6386611,"accession":"0000899243-22-035311","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-035311","line_url":"/filing/0000899243-22-035311#line-3","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8828.0,"shares_display":"8,828","price_per_share":15.7991,"price_display":"15.80","price_state":"stated","total_value":139474.4548,"total_display":"139,474.45","total_whole":"139,474","shares_owned_after":17110.0,"shares_owned_after_display":"17,110","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-04","filed_date":"2022-11-07","scope":"insider"},{"id":6386607,"accession":"0000899243-22-035311","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-035311","line_url":"/filing/0000899243-22-035311","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14165.0,"shares_display":"14,165","price_per_share":15.747153653370985,"price_display":"15.75","price_state":"stated","total_value":223058.4315,"total_display":"223,058.43","total_whole":"223,058","shares_owned_after":29021.0,"shares_owned_after_display":"29,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-03","filed_date":"2022-11-07","scope":"insider","n_lines":2},{"id":6878367,"accession":"0000899243-22-034840","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-034840","line_url":"/filing/0000899243-22-034840#line-2","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1544.0,"shares_display":"1,544","price_per_share":15.0664,"price_display":"15.07","price_state":"stated","total_value":23262.5216,"total_display":"23,262.52","total_whole":"23,263","shares_owned_after":4907.0,"shares_owned_after_display":"4,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-02","filed_date":"2022-11-02","scope":"insider"},{"id":6878363,"accession":"0000899243-22-034840","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-034840","line_url":"/filing/0000899243-22-034840#line-1","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2688.0,"shares_display":"2,688","price_per_share":15.3879,"price_display":"15.39","price_state":"stated","total_value":41362.6752,"total_display":"41,362.68","total_whole":"41,363","shares_owned_after":6451.0,"shares_owned_after_display":"6,451","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-31","filed_date":"2022-11-02","scope":"insider"},{"id":6319123,"accession":"0000899243-22-034497","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-034497","line_url":"/filing/0000899243-22-034497#line-2","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1683.0,"shares_display":"1,683","price_per_share":15.0876,"price_display":"15.09","price_state":"stated","total_value":25392.4308,"total_display":"25,392.43","total_whole":"25,392","shares_owned_after":4907.0,"shares_owned_after_display":"4,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-28","filed_date":"2022-10-28","scope":"insider"},{"id":6319120,"accession":"0000899243-22-034497","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-034497","line_url":"/filing/0000899243-22-034497#line-1","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":924.0,"shares_display":"924","price_per_share":15.3571,"price_display":"15.36","price_state":"stated","total_value":14189.9604,"total_display":"14,189.96","total_whole":"14,190","shares_owned_after":6590.0,"shares_owned_after_display":"6,590","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-27","filed_date":"2022-10-28","scope":"insider"},{"id":6741944,"accession":"0000899243-22-034294","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-034294","line_url":"/filing/0000899243-22-034294#line-4","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1678.0,"shares_display":"1,678","price_per_share":15.1025,"price_display":"15.10","price_state":"stated","total_value":25341.995,"total_display":"25,342.00","total_whole":"25,342","shares_owned_after":4907.0,"shares_owned_after_display":"4,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-26","filed_date":"2022-10-26","scope":"insider"},{"id":6741941,"accession":"0000899243-22-034294","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-034294","line_url":"/filing/0000899243-22-034294","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4806.0,"shares_display":"4,806","price_per_share":15.745366666666667,"price_display":"15.75","price_state":"stated","total_value":75672.2322,"total_display":"75,672.23","total_whole":"75,672","shares_owned_after":7119.0,"shares_owned_after_display":"7,119","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-25","filed_date":"2022-10-26","scope":"insider","n_lines":2},{"id":6741935,"accession":"0000899243-22-034294","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-034294","line_url":"/filing/0000899243-22-034294#line-1","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2866.0,"shares_display":"2,866","price_per_share":16.1701,"price_display":"16.17","price_state":"stated","total_value":46343.5066,"total_display":"46,343.51","total_whole":"46,344","shares_owned_after":11391.0,"shares_owned_after_display":"11,391","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-24","filed_date":"2022-10-26","scope":"insider"},{"id":6974699,"accession":"0000899243-22-034092","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-034092","line_url":"/filing/0000899243-22-034092","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13951.0,"shares_display":"13,951","price_per_share":16.360115575944377,"price_display":"16.36","price_state":"stated","total_value":228239.9724,"total_display":"228,239.97","total_whole":"228,240","shares_owned_after":7257.0,"shares_owned_after_display":"7,257","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-21","filed_date":"2022-10-24","scope":"insider","n_lines":2},{"id":6974692,"accession":"0000899243-22-034092","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-034092","line_url":"/filing/0000899243-22-034092","is_derivative":false,"issuer_cik":"0001880438","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001880438","owner_cik":"0001914503","owner_name":"Easom Eric","owner_display_name":"Easom Eric","owner_url":"/insider/0001914503","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7293.0,"shares_display":"7,293","price_per_share":16.683371452077335,"price_display":"16.68","price_state":"stated","total_value":121671.828,"total_display":"121,671.83","total_whole":"121,672","shares_owned_after":18889.0,"shares_owned_after_display":"18,889","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-20","filed_date":"2022-10-24","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":26,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":23,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":26},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001880438","name":"AN2 Therapeutics, Inc.","url":"/issuer/0001880438","role":"Director, Officer (Chief Executive Officer)","n_filings":11,"first_seen":"2022-10-24","last_seen":"2025-06-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001914503","retrieved_at":"2026-08-27T03:50:33+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}